Global Hemoglobinopathies Market Growth (Status and Outlook) 2023-2029

Global Hemoglobinopathies Market Growth (Status and Outlook) 2023-2029

Hemoglobinopathy or Hemoglobinopathies is the medical term for a group of blood disorders and diseases that affect red blood cells. It can be a kind of genetic defect that results in abnormal structure of one of the globin chains of the hemoglobin molecule.

LPI (LP Information)' newest research report, the “Hemoglobinopathies Industry Forecast” looks at past sales and reviews total world Hemoglobinopathies sales in 2022, providing a comprehensive analysis by region and market sector of projected Hemoglobinopathies sales for 2023 through 2029. With Hemoglobinopathies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hemoglobinopathies industry.

This Insight Report provides a comprehensive analysis of the global Hemoglobinopathies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hemoglobinopathies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hemoglobinopathies market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hemoglobinopathies and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hemoglobinopathies.

The global Hemoglobinopathies market size is projected to grow from US$ 268.5 million in 2022 to US$ 369.6 million in 2029; it is expected to grow at a CAGR of 4.7% from 2023 to 2029.

Increasing cases of hemoglobinopathies, especially in regions such as Southeast Asia and Africa, is one of the major growth drivers.

This report presents a comprehensive overview, market shares, and growth opportunities of Hemoglobinopathies market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Blood Transfusion
Iron Chelation Therapy
Bone Marrow Transplant
Others

Segmentation by application
Blood Testing
Genetic Testing
Pre-Implantation Genetic Diagnosis (PGD)
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Gamida Cell
Alnylam Pharmaceuticals
Sanofi
Sangamo Therapeutics Inc.
Global Blood Therapeutics
Bluebird Bio
Emmaus Life Sciences Inc.
Prolong Pharmaceuticals
Celgene Corporation

Please note: The report will take approximately 2 business days to prepare and deliver.